[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adult-subject\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adult-subject":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100602984",false,"NCT07130617","Evaluation of the Efficacy and Safety of Megestrol Acetate in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy","A Phase Ib, Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Group Clinical Study Evaluating the Efficacy and Safety of Megestrol Acetate Oral Suspension in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy","Inclusion Criteria:\n\n1. Age ≥ 18 years, regardless of sex\n2. Histologically or cytologically confirmed lung cancer\n3. Expected survival ≥ 3 months\n4. Female subjects of childbearing potential must have negative serum pregnancy test within 72 hours prior to randomization and must be non-lactating\n5. Capable of comprehending and willingly providing signed informed consent form (ICF), and adhering to study requirements\u002Frestrictions Exclusion Criteria\n\n1\\. Received or scheduled to receive concurrent radiotherapy within 7 days prior to enrollment through Day 1-8 of treatment 2. Systemic corticosteroid therapy or sedating antihistamines within 7 days prior to enrollment 3. Poorly controlled serous cavity effusions (pleural\u002Fperitoneal\u002Fpericardial) 4. Severe cardiovascular diseases within 3 months prior to enrollment 5. Participation in other clinical trials within 30 days prior to enrollment","ALL","18 Years",{"count":18,"type":19},132,"ESTIMATED","INTERVENTIONAL",[22],"PHASE1","To evaluate the efficacy of Megestrol Acetate Oral Suspension in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy in Malignant Solid Tumor Patients",[25,26,27,28],"Efficacy","Safety","Megestrol Acetate","Adult Subject","NOT_YET_RECRUITING","2025-08-12",{"date":32,"type":33},"2025-08-19","ACTUAL",{"date":35,"type":19},"2025-09-29",{"date":37,"type":19},"2026-07-31",{"name":39,"class":40},"Changchun GeneScience Pharmaceutical Co., Ltd.","INDUSTRY",""]